Nasdaq

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting First patient expected to be treated in the first half of 2024 "CT-0525 is the first CAR-Monocyte to be evaluated ...
Nasdaq

Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors

PHILADELPHIA, June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing ...
Investing

Guangshen Railway Co Ltd (0525)

Guangshen Railway Co Ltd stock price live, this page displays HK 0525 stock exchange data. View the 0525 premarket stock price ahead of the market session or assess the after hours quote. Monitor the ...